Biden’s SOTU Should Champion Competition Agenda Wins
March 1, 2024 — Ahead of the 2024 State of the Union, the American Economic Liberties Project released a new memo looking back at the successes of the Biden Administration’s revolutionary competition agenda, and calling on the President to highlight these victories in his address on March 7.
Congress Must Support DOJ Antitrust Division, Not Kneecap Them, to Curb Concentrated Corporate Power
March 4, 2024 — In response to the latest slate of government budget details negotiated by Congress, which includes a disastrous 20% proposed cut to the Department of Justice Antitrust Division’s budget—roughly $45 million less than enforcers were expected to receive—the American Economic Liberties Project released the following statement.
FTC and State AGs Sue to Block Kroger-Albertsons Merger, Protecting Consumers from Soaring Grocery Bills
February 26, 2024 — In response to news that the Federal Trade Commission (FTC) and a bipartisan group of 9 state attorneys general have sued to block grocery store Kroger’s $26.4 billion acquisition of its competitor, Albertsons, the American Economic Liberties Project released the following statement.
American Banker: Big banks charge higher credit card APRs than smaller issuers, CFPB says
February 18, 2024 — Morgan Harper is quoted in coverage of the CFPB's report finding that the largest credit card issuers charge significantly higher APRs than smaller issuers.
FTC and HHS Crack Down on Consolidated GPOs’ Role in Drug Shortages
February 14, 2024 — in response to news that the Federal Trade Commission and Department of Health and Human Services (HHS) have launched a request for information on how pharmaceutical middlemen known as group purchasing organizations (GPOs) and wholesalers contribute to shortages of crucial drugs, the American Economic Liberties Project released the following statement. As mentioned in the Wall Street Journal, Economic Liberties previously sent a letter to the FTC urging them to investigate the role of GPOs in drug shortages and rising healthcare costs in 2022, and recently detailed the market power of these middlemen in a policy brief, “The Dirty Secret of Drug Shortages.”